Table 2.
IgG+ N = 15 |
IgG- N = 179 |
IgM+ N = 36 |
IgM- N = 158 |
IgA+ N = 16 |
IgA- N = 178 |
|
---|---|---|---|---|---|---|
Female, n (%) | 13 (87) | 142 (80) | 31 (86) | 124 (79) | 10 (63) | 145 (82) |
Age (years), mean (SD) | 52 (16) | 55 (13) | 55 (15) | 55 (13) | 57 (10) | 55 (14) |
Disease duration since non-RP (months), median (IQR) | 92 (40; 160) | 43 (22; 122) | 46 (22; 98) | 45 (23; 136) | 45 (20; 70) | 46 (24; 138) |
Disease duration since RP, (months), median (IQR) | 116 (61; 239) | 98 (45; 232) | 85 (40; 223) | 112 (48; 239) | 64 (32; 163) | 110 (48; 232) |
Anti-topoisomerase antibodies, n (%) | 5 (33) | 39 (22) | 11 (31) | 33 (22) | 7 (44) | 37 (21) |
Anti-centromere antibodies, n (%) | 5 (33) | 75 (43) | 18 (50) | 62 (40) | 5 (31) | 75 (43) |
Modified Rodnan Skin Score, median (IQR) | 7 (0; 10) | 2 (0; 6) | 2 (0; 6) | 3 (1; 8) | 3 (0; 6) | 2 (0; 6) |
Disease subset, n (%) | ||||||
• Non cutaneous | 2 (6) | 34 (94) | 6 (17) | 30 (83) | 3 (8) | 33 (92) |
• Limited cutaneous | 8 (7) | 111 (93) | 22 (19) | 97 (82) | 9 (8) | 110 (92) |
• Diffuse cutaneous | 5 (13) | 34 (87) | 8 (21) | 31 (80) | 4 (10) | 35 (90) |
Synovitis, n (%) | 1 (7) | 11 (6) | 3 (8) | 9 (6) | 1 (6) | 11 (6) |
Anti-CarP anti-carbamylated protein antibodies, SSc systemic sclerosis, N number, SD standard deviation, IQR interquartile range